|
Hampton holds Bachelor of Science degree in marketing from University of Florida. He has also worked with several leading pharmaceutical companies, including Osmotica Pharmaceuticals, Dabur Pharma and IVAX Pharmaceuticals.
Hampton joins PCC from Accord Healthcare, where he was the president and responsible for accelerating the firm's growth strategy. Prior to that, he was the senior vice president and general manager at Apotex for the US and Latin America regions. At Apotex, Hampton restructured the US commercial team to maximize efficiency and established procedures for identifying and executing life cycle management practices to improve profitability and market penetration.
His career, so far, spans over three decades across sales and marketing, regulatory, commercial operations, sales strategy, distribution, and business development.
Peter DeYoung, CEO, Global Pharma, Piramal Pharma, said, “His experience across the domains of sales and marketing will help us develop stronger, long-term global operations strategies to deliver profitable growth. His expertise across functions augurs well for the business, as we set our sight to further reinforce PCC's position as a leading global player in complex hospital generics.”
Speaking on the occasion of joining PCC, Hampton, said, “It is truly an honor to be joining such a fast-paced, growth-oriented global company like Piramal Critical Care. I look forward to leading PCC's growth strategies to expand our presence.”
Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, PPL received 20% strategic growth investment from the Carlyle Group
The company reported consolidated net profit of Rs 50.11 crore in Q4 FY23 as against a net loss of Rs 90.18 crore in Q3 FY23. Revenue from operations rose 26.08% quarter on quarter to Rs 2,163.58 crore in the quarter ended 31 March 2023.
The scrip declined 2.38% to Rs 87.20 on the BSE.
|